about
Fabp7 maps to a quantitative trait locus for a schizophrenia endophenotype.A common variant in the 3'UTR of the GRIK4 glutamate receptor gene affects transcript abundance and protects against bipolar disorderNootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulatorsPreclinical models of antipsychotic drug action.Blonanserin ameliorates phencyclidine-induced visual-recognition memory deficits: the complex mechanism of blonanserin action involving D₃-5-HT₂A and D₁-NMDA receptors in the mPFC.Role of NMDA Receptor-Mediated Glutamatergic Signaling in Chronic and Acute NeuropathologiesCommon mechanisms of excitatory and inhibitory imbalance in schizophrenia and autism spectrum disordersAntipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotectionImpaired limbic cortico-striatal structure and sustained visual attention in a rodent model of schizophrenia.Anhedonia, avolition, and anticipatory deficits: assessments in animals with relevance to the negative symptoms of schizophrenia1-aminocyclopropanecarboxylic acid (ACPC) produces procognitive but not antipsychotic-like effects in rats.How Nox2-containing NADPH oxidase affects cortical circuits in the NMDA receptor antagonist model of schizophrenia.Reduction in phencyclidine induced sensorimotor gating deficits in the rat following increased system xc⁻ activity in the medial prefrontal cortex.Animal models of serotonergic psychedelics.Removal of GABA(A) receptor γ2 subunits from parvalbumin neurons causes wide-ranging behavioral alterations.Glycine transport inhibitors for the treatment of schizophreniaNeuromapping techniques in drug discovery: pharmacological MRI for the assessment of novel antipsychotics.Impaired fear memory specificity associated with deficient endocannabinoid-dependent long-term plasticity.A role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in miceAntipsychotic drug action: targets for drug discovery with neurochemical imaging.Dizocilpine (MK-801) induces distinct changes of N-methyl-D-aspartic acid receptor subunits in parvalbumin-containing interneurons in young adult rat prefrontal cortexCannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research.Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in ratsPreparation and analytical characterization of 1-(1-phenylcyclohexyl)piperidine (PCP) and 1-(1-phenylcyclohexyl)pyrrolidine (PCPy) analogues.Reviewing the ketamine model for schizophrenia.Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs.In vitro and in vivo characterization of a novel negative allosteric modulator of neuronal nAChRsKetamine and phencyclidine: the good, the bad and the unexpected.Maternal influenza viral infection causes schizophrenia-like alterations of 5-HT₂A and mGlu₂ receptors in the adult offspring.New insight in expression, transport, and secretion of brain-derived neurotrophic factor: Implications in brain-related diseases.Parvalbumin-positive interneurons of the prefrontal cortex support working memory and cognitive flexibilityOlanzapine Prevents the PCP-induced Reduction in the Neurite Outgrowth of Prefrontal Cortical Neurons via NRG1Persistent effects of chronic clozapine on the cellular and behavioral responses to LSD in miceAcute cognitive effects of high doses of dextromethorphan relative to triazolam in humansDopamine D1 receptor activation improves PCP-induced performance disruption in the 5C-CPT by reducing inappropriate responding.Subanaesthetic ketamine treatment alters prefrontal cortex connectivity with thalamus and ascending subcortical systems.NMDA hypofunction as a convergence point for progression and symptoms of schizophreniaHigh doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogensSynthesis and structure activity relationship of tetrahydroisoquinoline-based potentiators of GluN2C and GluN2D containing N-methyl-D-aspartate receptorsDo NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?
P2860
Q21092751-5BC0A465-799B-443B-B3D4-7E9795AA1335Q24652421-D8E92665-7FD5-4B8A-8E34-740DA636C4EDQ24681828-693A40B1-498D-4A37-84D7-D3A2C43C3CA6Q26827502-A0D18366-5CAB-42BB-8FFA-C73B337DCE55Q27311205-4A6B7E03-8869-4658-8DBB-0C75B1D280B8Q28072353-1FA009CD-F0B2-46F5-9EEB-5902F3D9F4D9Q28086869-BE53F77C-E6B6-4CC5-A171-80FCE701045FQ30386608-F0E71564-8892-4168-8E84-86364153C53EQ30403790-C6F459D5-9C02-4207-B8D5-00DAE16128D8Q30413012-7F998673-7748-4C02-9B50-E96941B3648EQ30418172-4E056B5D-8AE7-48E1-B45A-11BE186F4198Q30439924-F82C8DA8-41C7-4C27-84BC-7AC3AF3E52CAQ30440988-3A4606F8-C718-42B2-90EE-0A853F7E8D55Q30444312-298A0E62-E86D-411C-B3CA-7CC624BBA551Q30474166-E94407A6-B00D-4399-92B7-A0431DCB4AA2Q30477522-D1497535-C351-4105-A574-9AC11FC805C2Q30564474-7B69767D-D198-4B31-8E3B-81058DBEF1E0Q30578265-1A68EDC6-29EA-4B9C-9607-92177BC72D66Q30651885-578D24E5-871E-4AFD-9FD1-0F9EFAE32F15Q31032036-2685994B-2A8E-4CA0-B00F-4579F2D31BB0Q33444363-07D0F58A-B902-442A-ABD1-98646C3F4C8FQ33819365-F8064A2E-4115-4F84-BE1B-92924C4D7DE5Q33848200-858E32CE-9144-4C4E-B613-19D5D43C70DFQ34036232-64CF7ED4-74D7-452C-8CC5-ED41681BD0F2Q34046060-40FB45BD-FB83-47F0-856D-4215EB41D1FEQ34236107-A3BED7C9-6CD0-4FA9-8991-7B330CBA0067Q34387101-780E8349-5432-44B1-BA3C-D6C10FC951CDQ34480719-2E771570-63BC-4748-8555-A8C150F36FDCQ34566313-A0A1CAFD-DDE9-4432-8C7C-C3BBFEB5D8D7Q34567939-3C4FC784-6F47-4F52-AC5D-B3797523B99BQ36320716-D95B3FDC-E3CA-40B1-AF4A-3634A5DB75AFQ36500134-21E6E301-1AD8-48E3-923A-A12D419BBD77Q36555130-76FF4615-6A81-4C1D-B37B-3DE9EA18E9B4Q36582340-3E08565E-9F1D-4B50-9A44-E2B402605B95Q36618769-5C3BA12D-1BD6-4D05-BCBD-F5B1240445B8Q36621080-41B2618A-6241-4A3E-92F2-5EB90FB206B4Q36718684-A6544CA8-7262-4E5C-A481-2240405DC2B0Q36839080-C8D0734A-AE35-42D1-AE74-15A483ED3CA6Q36851341-08177BF8-FE4A-47A1-872F-45413338CAADQ36860053-B4BC1C36-F845-42CD-BB95-A662DB8889E2
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
PCP: from pharmacology to modelling schizophrenia.
@ast
PCP: from pharmacology to modelling schizophrenia.
@en
type
label
PCP: from pharmacology to modelling schizophrenia.
@ast
PCP: from pharmacology to modelling schizophrenia.
@en
prefLabel
PCP: from pharmacology to modelling schizophrenia.
@ast
PCP: from pharmacology to modelling schizophrenia.
@en
P2093
P1476
PCP: from pharmacology to modelling schizophrenia.
@en
P2093
Brian J Morris
Judith A Pratt
Susan M Cochran
P304
P356
10.1016/J.COPH.2004.08.008
P577
2005-02-01T00:00:00Z